Li Shuangping, Li Jingjing, Li Yumeng, Ye Qingping, Wang Ruru, Liu Xinyao, Li Huining, Peng Daiyin, Duan Xianchun
Department of Pharmacy, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, PR China; School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, PR China.
School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, PR China; Xin'an Medical Research Institute, Hefei, 230038, PR China; Key Laboratory of Xin'An Medicine, Ministry of Education, Hefei, 230012, PR China; Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, 230012, PR China; MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Hefei, 230012, PR China; Anhui Province Modern Chinese Medicine Industry Common Technology Research Center, Hefei, 230012, PR China.
J Ethnopharmacol. 2025 Jul 11;353(Pt A):120285. doi: 10.1016/j.jep.2025.120285.
Taohong Siwu Decoction (THSWD), a classic prescription, is commonly used to treat ischemic stroke. However, the effects of THSWD on endothelial cells (ECs) in cerebral ischemia-reperfusion injury (IRI) are unclear.
This study investigated whether THSWD can protect ECs from cerebral IRI by regulating NR4A1 to mitigate mitochondrial fission and reduce cell apoptosis.
We established the rat MCAO model and the OGD/R injury model of human BMECs cells. Observation of the protective effect of THSWD against IRI using Zea-Longa score, TTC staining, and HE staining; ELISA to detect ET-1, eNOS level; immunofluorescence to detect vWF, claudin-5, occludin in brain tissue; CCK8 to detect cell viability; transmission electron microscopy to observe mitochondrial morphology; Expression of mitochondrial division and apoptosis-related proteins and mRNAs detected by WB and RT-qPCR; immunohistochemistry to detect the expression of NR4A1 and Caspase9, ROS content was detected by flow cytometry; mitochondrial membrane permeability colorimetric assay kit was used to observe the degree of mitochondrial mPTP opening; and endothelial cell permeability was measured by FITC-dextran; Meanwhile, public database data analysis, chromatin immunoprecipitation and luciferase gene reporter techniques were used to analyze and validate the NR4A1-Mff binding relationship, and molecular docking techniques and molecular dynamics simulations were used to validate the docking activity of NR4A1 with THSWD active ingredients.
In the model group, vascular endothelial damage, mitochondrial structure impairment, increased opening of mPTP, elevated ROS levels, and upregulated NR4A1, Mff, and Drp1 expression at both the mRNA and protein levels, as well as increased apoptosis-related protein expression. After THSWD administration, vascular endothelial damage was improved. Mitochondrial damage was alleviated, degree of mPTP opening was reduced, ROS content was decreased, and NR4A1, Mff, and Drp1 expression at both the mRNA and protein levels was downregulated, along with a reduction in the expression of apoptosis-related proteins. NR4A1 was able to bind specifically to the R2 region of the Mff gene promoter. In microvascular endothelial cells with high expression of NR4A1, the transcriptional activity of the promoter region of the Mff gene was significantly enhanced, whereas THSWD-containing serum inhibited the activation of the Mff gene promoter region by NR4A1. Quercetin and kaempferol had a strong binding capacity to NR4A1, and the complexes remained stable during molecular dynamics simulations.
During cerebral IRI, NR4A1 promotes excessive mitochondrial fission in vascular ECs, leading to apoptosis. THSWD can protect vascular ECs by inhibiting NR4A1, reducing excessive mitochondrial fission, and suppressing cell apoptosis.
桃红四物汤(THSWD)是一种经典方剂,常用于治疗缺血性中风。然而,THSWD对脑缺血再灌注损伤(IRI)中内皮细胞(ECs)的作用尚不清楚。
本研究探讨THSWD是否能通过调节NR4A1减轻线粒体分裂并减少细胞凋亡,从而保护ECs免受脑IRI损伤。
我们建立了大鼠大脑中动脉闭塞(MCAO)模型和人脑微血管内皮细胞(BMECs)的氧糖剥夺/复氧(OGD/R)损伤模型。采用Zea-Longa评分、TTC染色和HE染色观察THSWD对IRI的保护作用;ELISA检测ET-1、eNOS水平;免疫荧光检测脑组织中vWF、claudin-5、occludin;CCK8检测细胞活力;透射电子显微镜观察线粒体形态;通过蛋白质免疫印迹(WB)和逆转录定量聚合酶链反应(RT-qPCR)检测线粒体分裂和凋亡相关蛋白及mRNA的表达;免疫组化检测NR4A1和Caspase9的表达,流式细胞术检测ROS含量;使用线粒体膜通透性比色测定试剂盒观察线粒体mPTP开放程度;通过FITC-葡聚糖测量内皮细胞通透性;同时,利用公共数据库数据分析、染色质免疫沉淀和荧光素酶基因报告技术分析和验证NR4A1-Mff结合关系,并采用分子对接技术和分子动力学模拟验证NR4A1与THSWD活性成分的对接活性。
在模型组中,血管内皮损伤、线粒体结构受损、mPTP开放增加、ROS水平升高,NR4A1、Mff和Drp1在mRNA和蛋白质水平的表达上调,以及凋亡相关蛋白表达增加。给予THSWD后,血管内皮损伤得到改善。线粒体损伤减轻,mPTP开放程度降低,ROS含量减少,NR4A1、Mff和Drp1在mRNA和蛋白质水平的表达下调,同时凋亡相关蛋白的表达减少。NR4A1能够特异性结合Mff基因启动子的R2区域。在NR4A1高表达的微血管内皮细胞中,Mff基因启动子区域的转录活性显著增强,而含THSWD的血清抑制了NR4A1对Mff基因启动子区域的激活。槲皮素和山奈酚与NR4A1具有很强的结合能力,并且在分子动力学模拟过程中复合物保持稳定。
在脑IRI过程中,NR4A1促进血管ECs中过度的线粒体分裂,导致细胞凋亡。THSWD可通过抑制NR4A1、减少过度的线粒体分裂和抑制细胞凋亡来保护血管ECs。